BLUESTONE
ActiveSummary
BLUESTONE has been active since 2000 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.5m and a net result of -€10,933. Equity has been shrinking by about 2.8% per year since 2018. Its solvency ranks better than 28% of 39,293 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 31-10-2000 Normal situation
- Registered office
- 11 active companies are registered at this address Source: KBO register, as of 4 November 2026.
- Activity
- Activities of head offices NACE 70100and 1 other
- Establishment unit
- 2.171.317.383 1050 Elsene, since 01-01-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Board and ownership
- Paul RANSARTDirector · since 01-06-2016
- Holdings
- Shares in 9 companies including Société de Participations et de Gestion Financières et Immobilières and PHARMANEXT
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.5%
- Gross margin
- €278,349
- ▼ 64.7%
- Turnover
- ≈ €400,000
- estimated
- Loss
- €10,933
- Equity
- €2.5m
- ▼ 0.4%
- Total assets
- €9.5m
- ▼ 0.7%
- Employees on 31-12-2025
- 1
- =
Score breakdownraises riskLiquidity: current ratio 0.20, cash €6,1761 of the last 3 accounts latelowers riskSize: total assets €9.5mSector: Activities of head offices; management consultancy activities (NACE 70)Show the evidence
Checked score
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, small). It does better than 27% of them on solvency, 7% on liquidity, 15% on profitability and 29% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 43 days after the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 24-07-2026 at the NBB all 25 filings
Every figure per financial year
The operating result for 2025 is 4% lower than in 2024. It is the second fall in a row.
- 2023 Net result +247% on 2022. The accounts now follow the micro format, last year the full format.
The turnover shown is an estimate from the gross margin.
Staff
| Item | 31-12-2022 | 31-12-2023 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|---|
| Employees at the balance-sheet date | 1 | 1 | 1 | 1 |
| full-time | 1 | 1 | 1 | 1 |
| part-time | - | 0 | 0 | 0 |
| in full-time equivalents | 1 | 1 | 1 | 1 |
| Average over the year, in full-time equivalents | 0.7 | 0 | 1 | 1 |
| On a permanent contract | 1 | 1 | 1 | 1 |
| Joined | 1 | 1 | - | 1 |
| Left | 0 | 1 | - | 1 |
Source: social balance sheet in the 2022 to 2025 annual accounts
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €31,641 | €43,564 | €16,446 | €618,076 | €1,391 |
| Financial fixed assets | - | - | €300,250 | €3.7m | €0 |
| Depreciation and write-downs of the year | €21,395 | €28,394 | €31,872 | €36,595 | €42,552 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | €4,400 | €571,048 | €0 | ▼ 100% |
| Remuneration, social security and pensions62 | - | - | - | - | €44,195 | €62,486 | €56,873 | €70,827 | ▲ 24.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €7,043 | €16,066 | €15,901 | €21,395 | €28,394 | €31,872 | €36,595 | €42,552 | ▲ 16.3% |
| Other operating charges640/8 | - | - | - | €1,051 | €3,850 | €2,047 | €1,334 | €1,062 | ▼ 20.4% |
| Non-recurring operating charges66A | - | - | - | - | - | - | €522,082 | €0 | ▼ 100% |
| Gross operating margin9900 | €125,091 | €190,855 | €172,673 | €181,047 | €185,580 | €388,192 | €787,892 | €278,349 | ▼ 64.7% |
| Operating profit (loss)9901 | €116,702 | €173,304 | €155,780 | €158,601 | €109,140 | €291,787 | €171,009 | €163,908 | ▼ 4.2% |
| Financial income75/76B | - | - | - | €2,906 | €10,759 | €8,303 | €6,926 | €19,959 | ▲ 188% |
| Recurring financial income75 | €9,886 | €13,788 | €4,245 | €2,906 | €10,759 | €8,303 | €6,926 | €19,959 | ▲ 188% |
| Financial charges65/66B | - | - | - | €41,852 | €40,881 | €56,301 | €108,492 | €194,076 | ▲ 78.9% |
| Recurring financial charges65 | €57,842 | €50,973 | €41,139 | €41,852 | €40,881 | €56,301 | €108,492 | €194,076 | ▲ 78.9% |
| Profit (loss) for the period before taxes9903 | €68,745 | €136,119 | €118,885 | €119,656 | €79,018 | €243,789 | €69,443 | -€10,208 | - |
| Income taxes67/77 | €7,668 | €27,784 | €32,306 | €32,795 | €26,867 | €62,848 | €23,994 | €725 | ▼ 97.0% |
| Profit (loss) for the period9904 | €61,077 | €108,335 | €86,579 | €86,861 | €52,151 | €180,941 | €45,450 | -€10,933 | - |
| Transfer to tax-exempt reserves689 | - | - | - | - | - | - | - | €58,940 | - |
| Profit (loss) for the period to be appropriated9905 | €61,077 | €108,335 | €86,579 | €86,861 | €52,151 | €180,941 | €45,450 | -€69,873 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €4.7m | €4.9m | €4.9m | €5.0m | €5.1m | €5.4m | €9.6m | €9.5m | ▼ 0.7% |
| Fixed assets21/28 | €4.5m | €4.6m | €4.6m | €4.6m | €4.6m | €4.6m | €8.3m | €8.3m | ▼ 0.5% |
| Tangible fixed assets22/27 | €165 | €0.06m | €0.04m | €0.05m | €0.07m | €0.05m | €0.1m | €0.07m | ▼ 36.5% |
| Land and buildings22 | - | - | - | - | - | - | €0.06m | €0.04m | ▼ 30.1% |
| Furniture and vehicles24 | - | - | - | €0.03m | €0.06m | €0.05m | €0.05m | €0.03m | ▼ 44.7% |
| Leasing and similar rights25 | - | - | - | €0.02m | €0.01m | €0 | - | - | - |
| Financial fixed assets28 | €4.5m | €4.5m | €4.5m | €4.5m | €4.5m | €4.5m | €8.2m | €8.2m | = |
| Current assets29/58 | €0.2m | €0.3m | €0.3m | €0.4m | €0.5m | €0.8m | €1.2m | €1.2m | ▼ 2.1% |
| Amounts receivable after more than one year29 | - | - | - | - | - | - | €0.6m | €0.5m | ▼ 4.8% |
| Other amounts receivable291 | - | - | - | - | - | - | €0.6m | €0.5m | ▼ 4.8% |
| Amounts receivable within one year40/41 | €0.2m | €0.3m | €0.3m | €0.4m | €0.5m | €0.8m | €0.7m | €0.6m | ▼ 1.9% |
| Trade receivables40 | - | - | - | €0.08m | €0.2m | €0.4m | €0.3m | €0.2m | ▼ 49.8% |
| Other amounts receivable41 | - | - | - | €0.3m | €0.3m | €0.4m | €0.3m | €0.5m | ▲ 48.1% |
| Cash at bank and in hand54/58 | €496 | €0.003m | €0.006m | €0.01m | €0.008m | €0.005m | €0.009m | €0.006m | ▼ 30.6% |
| Deferred charges and accrued income490/1 | - | - | - | €0.003m | €0.006m | €0.004m | €0.006m | €0.02m | ▲ 293% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €4.7m | €4.9m | €4.9m | €5.0m | €5.1m | €5.4m | €9.6m | €9.5m | ▼ 0.7% |
| Equity10/15 | €3.1m | €3.1m | €3.2m | €3.3m | €3.4m | €2.5m | €2.6m | €2.5m | ▼ 0.4% |
| Contributions10/11 | €3.1m | €3.1m | - | €3.1m | €3.1m | €2.1m | €2.1m | €2.1m | = |
| Reserves13 | €0.003m | €0.008m | €0.008m | €0.008m | €0.06m | €0.06m | €0.1m | €0.2m | ▲ 55.8% |
| Non-distributable reserves130/1 | - | - | - | €0.008m | €0.008m | €0 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €0.008m | €0.008m | €0 | - | - | - |
| Tax-exempt reserves132 | - | - | - | - | - | - | - | €0.06m | - |
| Distributable reserves133 | - | - | - | - | €0.05m | €0.06m | €0.1m | €0.1m | = |
| Profit (loss) carried forward14 | -€0.04m | €0.01m | €0.1m | €0.2m | €0.2m | €0.3m | €0.3m | €0.3m | ▼ 20.5% |
| Amounts payable17/49 | €1.7m | €1.8m | €1.7m | €1.7m | €1.8m | €2.9m | €7.0m | €7.0m | ▼ 0.8% |
| Amounts payable after more than one year17 | €0.5m | €0.8m | €0.7m | €0.6m | €0.4m | €0.8m | €1.1m | €0.9m | ▼ 23.3% |
| Financial debts170/4 | - | - | - | €0.6m | €0.4m | €0.8m | €1.1m | €0.9m | ▼ 23.3% |
| Amounts payable within one year42/48 | €1.2m | €0.9m | €1.0m | €1.1m | €1.3m | €2.1m | €5.9m | €6.1m | ▲ 3.6% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.2m | €0.2m | €0.3m | €0.3m | €0.3m | ▼ 19.3% |
| Financial debts43 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | = |
| Credit institutions430/8 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | = |
| Trade debts44 | €0.005m | €0.008m | €0.004m | €0.01m | €0.02m | €0.02m | €0.02m | €0.004m | ▼ 76.6% |
| Suppliers440/4 | - | - | - | €0.01m | €0.02m | €0.02m | €0.02m | €0.004m | ▼ 76.6% |
| Taxes, remuneration and social security45 | - | - | - | €0.02m | €0.03m | €0.1m | €0.09m | €0.03m | ▼ 71.7% |
| Taxes450/3 | - | - | - | €0.02m | €0.02m | €0.1m | €0.08m | €0.02m | ▼ 75.5% |
| Remuneration and social security454/9 | - | - | - | - | €0.006m | €0.003m | €0.01m | €0.007m | ▼ 50.9% |
| Other amounts payable47/48 | - | - | - | €0.8m | €1.0m | €1.6m | €5.3m | €5.6m | ▲ 6.7% |
| Accrued charges and deferred income492/3 | - | - | - | €0.001m | €0.002m | €0.003m | €0 | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.06m | €0.1m | €0.09m | €0.09m | €0.05m | €0.2m | €0.05m | -€0.01m | - |
| + Depreciation and write-downs630 | €0.007m | €0.02m | €0.02m | €0.02m | €0.03m | €0.03m | €0.04m | €0.04m | ▲ 16.3% |
| Operating cash flow (approximation) | €0.07m | €0.1m | €0.1m | €0.1m | €0.08m | €0.2m | €0.08m | €0.03m | ▼ 61.5% |
| Investment in fixed assets (approximation) | - | -€0.08m | €325 | -€0.03m | -€0.04m | -€0.02m | -€3.8m | -€0.001m | ▲ 100.0% |
| Change in cash | - | €0.003m | €0.003m | €0.008m | -€0.006m | -€0.003m | €0.004m | -€0.003m | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 25 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 24-07-2026 | 2026-00337851 | |
| 31-12-2024 | micro format | 28-08-2025 | 2025-00446514 | |
| 31-12-2023 | micro format | 20-10-2024 | 2024-00511535 | |
| 31-12-2022 | full format | 29-10-2023 | 2023-00501536 | |
| 31-12-2021 | full format | 31-08-2022 | 2022-20402380 | |
| 31-12-2020 | full format | 30-09-2021 | 2021-70100018 | |
| 31-12-2019 | full format | 16-08-2020 | 2020-42500205 | |
| 31-12-2018 | full format | 27-08-2019 | 2019-52800100 | |
| 31-12-2017 | full format | 30-08-2018 | 2018-54500472 | |
| 31-12-2016 | full format | 29-08-2017 | 2017-51900308 |
Board & ownership
Directors
Owners and capital
Capital transactions
- 05-04-2023 Converted to unavailable equity
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Paul RANSART |
|
Articles of association
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Moitié cédant moitié acquéreurs au prorata si plusieurs, nullité”
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Administrateurs en fonction désignés liquidateurs en vertu statuts si aucun autre désigné, assemblée peut désigner un ou plusieurs…”
Articles of association, deed of 05-04-2023 (in French)
Network & group
Holdings and subsidiaries
9 holdings · 10 subsidiaries, including indirect onesHoldings 9
Source for every holding own accounts 2025
- Equity €4.3m Profit of €3.0m in 2025 (profit of €654,080 in 2024) Checked score 9199.46%
- PHARMANEXTsubsidiaryEquity €531,183 Profit of €169,596 in 2025 (profit of €139,464 in 2024) Checked score 5580%
- PALATINEsubsidiaryEquity €487,128 Loss of €60,905 in 2025 (loss of €90,665 in 2024) Checked score 5151.44%
- Equity €25,342 Loss of €11,311 in 2025 (loss of €69,773 in 2024) Checked score 5150%
- Equity €719,922 Profit of €11,450 in 2025 (profit of €68,942 in 2024) Checked score 8549.97%
- Equity €729,499 Profit of €74,884 in 2025 (loss of €57,049 in 2024) Checked score 8231.3%
- Equity €175,559 Profit of €14,981 in 2025 (profit of €58,320 in 2024) Checked score 6424.2%
- Equity €1.2m Profit of €43,298 in 2025 (profit of €62,582 in 2024) Checked score 6318%
- Equity €260,087 Profit of €7,490 in 2025 (profit of €431 in 2024) Checked score 8210%
All subsidiaries, including indirect ones 10
BLUESTONE or one of its subsidiaries holds more than half of the shares of these companies. A company it consolidates per the LEI register is listed too.
- Société de Participations et de Gestion Financières et Immobilières 99.46%
PHARMANEXT 80%1 subsidiary
- ACLOT PHARMA 100%
PALATINE 51.44%6 subsidiaries
- CAPITOLIUM 100%
Europhar 100%1 subsidiary
PHARMARIVE 100%1 subsidiary
- DIGITALE 100%
- PHARMIMPULSE 100%
Board mandates elsewhere
11 board mandatesShow 5 more
Companies at the same address
10 other companies- ALEXANDRE ASSELIN Registered office · since 2025 1027456167
- BEWINES Establishment · since 2019 0737797143
- IMMOLENANS Establishment · since 2019 0433262871
- PHARMANEXT Registered office · since 2018 0705998068
- Delorme, Anne (sole trader) Establishment · since 2015 0544772586
- A.C.P. SOLBOSCH 30 ACP Registered office · since 2008 0850084145
- Elisamed SNC - Cabinet de médecine générale et d'expertise médicale - Docteurs JM DUMONT et ML TEICHMANN Registered office · since 2007 0891269652
- Société de Participations et de Gestion Financières et Immobilières Registered office · since 2004 0867364892
- Association des copropriétaires de l'immeuble sis à Ixelles, square du Solbosch 30 Registered office · since 1995 0844556036
- LES PHARMACIES RURALES Establishment · since 1991 0444082628
Connections & network
4 connected companiesTimeline
Acts, filings and financial milestones
05-04
Gazette deed
Change of role: Paul RANSART, from manager to directorAmendment of the articles · Capital conversion · Purpose change11 points ▸
- General meeting, 31-03-2023
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Capital conversion, “suppression du compte de capitaux propres statutairement indisponible, formes et majorités de la modification des statuts” (deed in French)
- Purpose change
- Capital
- Director appointment, Paul RANSART (director (not named in the articles))
- Director resignation, Paul RANSART (manager)
- Director discharge, Paul RANSART
- Registered office clause, “Square du Solbosch 30,1050 Ixelles” (deed in French)
- Power of attorney
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
NACEBEL 2025Codes under NACEBEL 2008
Codes under NACEBEL 2003
16 activities
- Toutes activités de conseils en matière de marketing, merchandising, aménagement, communication, management et gestion de points de vente et particulièrement ceux liés au domaine de la santé et du bien-être tels que officines pharmaceutiques, parapharmacie, herboristerie, centre d’esthétique, spa; cette énonciation étant exemplative et non limitative.
- L'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des Pharmaciens, et l'exploitation de laboratoires de recherches et d'analyse, de grossiste ou laboratoire pharmaceutique;
- L'achat, la vente, l'importation, l'exportation, la fabrication, l'industrialisation, la représentation, la distribution, la commercialisation et le commerce sous toutes ses formes de tous produits chimiques, pharmaceutiques, allopathiques ou homéopathiques, diététiques, phytopharmaceutiques et vétérinaires, de tous articles de droguerie, de parfumerie, de cosmétique, d'hygiène, d'herboristerie, d'entretien, de nettoyage et de désinfection, de tous appareils, instruments et accessoires de chirurgie, d'acoustique, d'optique et d'orthopédie, bandagisterie, système d'alarme et autres produits s'y rapportant d'une quelconque façon ou pouvant y être adjoint utilement, et, d'une manière générale, de tous appareils, accessoires, instruments produits ou procédés se rattachant directement ou indirectement à l'exploitation d'une officine pharmaceutique, d’une parapharmacie, d’une herboristerie, d’un centre de bien-être, d’un centre d’esthétique, d’un spa, ou d'un laboratoire de recherche et d'analyses, ainsi que la formation et les conseils en ces matières;
- L’achat et la vente de matériels, de matériaux, de mobiliers et d’aménagements liés aux activités décrites ci-avant;
- L'achat, la vente, l'échange, l'approbation, la concession, la constitution, le démembrement concernant tous biens ou droits réels immobiliers et toutes affaires relatives à ces biens, en ce compris l'exploitation, la gestion et la location de ces biens;
- La construction, la reconstruction, la transformation, la rénovation, l'aménagement, la démolition, ainsi que toute entreprise relativement aux biens immobiliers bâtis et non bâtis;
- Les expertises, études, les conseils, prêts et financements et opérations immobilières et de promotion;
- L'étude et la promotion immobilière et financière;
- La gestion de toutes sociétés commerciales belges ou étrangères;
- La prise de participations, majoritaires ou non, dans d'autres sociétés;
- La prise de participations dans toute entreprise, sous quelque forme que ce soit, l'exercice du contrôle, de la gestion, de l'administration, de la consultance favorisant la poursuite de l'objet de ces sociétés, notamment et dans la mesure de ces compétences par l'exercice de mandats sociaux ou non;
- La constitution, l'acquisition, la cession, la concession, la licence de droits de propriété industrielle, et de tous droits apparentés;
- L'importation et l'exportation de tous biens et services, le courtage international commercial, industriel, financier, mobilier et immobilier, et toute autre opération analogue par le mécanisme ou par les effets, ainsi que l'exercice à l'étranger, s'il y lieu, de toutes les activités ci-dessus énumérées;
- La gestion de bâtiments et équipements (« facilities management »), les services de gestion d'immeubles au sens large, y compris tous services de nettoyage, tant intérieur qu’extérieur, l’élaboration et l’entretien de parcs, jardins, tennis et piscines, sécurité, déménagement des lieux et autres services se rapportant à l'exploitation d'un immeuble tant pour compte propre que pour celui de tiers;
- La gestion et l'entretien de bois, de parcs, de jardins et de terres, d'étangs, de tennis, de piscines;
- L’achat, la vente, la location, l’importation, l’exportation de tous types de véhicules.
Invoicing and payment
Financial year and general meeting
Accounts at the NBBRecognitions · licences · registrations
Food safety, FASFC
1 siteSites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 21446D0194/00T007 | Brussels | 510 m² | 1 · 342 m² | 30.6 m · 8 |